Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Carl Heneghan

๐Ÿ‘ค Speaker
926 total appearances

Appearances Over Time

Podcast Appearances

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

How can anybody keep up to date?

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

It is incredibly difficult, and if not getting harder in the world, with the amount of information that's published.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Added to that is a bit of fake news.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Added to that is an overwhelming number of journals that are increasing.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So it's a real difficult problem.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

That's why you should listen to this podcast, because we distill it for you to some of the important stuff.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So it's interesting.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

I think this concept of putting an artificial line in the sand of 3% for me creates some problems because you talk about what happens if your risk is 2.9% versus 3.1% and I think that creates an issue.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

How can you interpret that small difference that you go over and above the threshold?

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

That means you should be tested.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So where I think this goes slightly wrong, so I like the paper, I like what they've done,

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

is when we talk about risk threshold, we're generally talking about we're going to offer it to the population at this risk.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Because all of the benefits come when you do it at the population level.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So if you take over 65-year-olds, there's about 20 million people you'd screen.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

And if you screened them, you'd save at 3%, you'd save about 36,000.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Yeah, so on average 3%, somewhere more or less.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

but you'd save about ยฃ36,000.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So the benefits of screening only come if you screen everybody because the individual benefits are small.

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

So if we all start talking about either side of the risk and making a decision, the question is then should we be screening at all?

Talk Evidence
Talk Evidence - aggravating acronyms, a time to prescribe, and screening (again)

Well, that's really interesting because I went, it said in the paper, it recommended the Q risk for cancer.